The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar ADCs and initial efficacy in heavily pretreated patients with advanced or metastatic solid tumors, according to interim data shared today at the 2024 European Society for Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center.
Pre-clinical studies provide important first steps to prepare for first clinical bladder transplant
A series of pre-clinical studies provide important first steps in developing techniques of robotic bladder transplantation in humans, as reported in the October issue of
September 8, 2023